SKPin C1

SKPin C1 is a small molecule inhibitor that targets the S-phase kinase-associated protein 2 (SKP2), a critical F-box protein component of the SCF (Skp, Cullin, F-box containing) E3 ubiquitin ligase complex. Its primary mechanism of action involves blocking the interaction between SKP2 and its substrate, the cyclin-dependent kinase inhibitor p27 (CDKN1B), thereby preventing the ubiquitination and subsequent proteasomal degradation of p27. By stabilizing p27 levels, SKPin C1 enhances the transcriptional activity of cytochrome b-245 heavy chain (CYBB), which facilitates drug-induced ferroptosis. Research indicates that SKPin C1 can significantly sensitize epithelial ovarian cancer (EOC) cells to platinum-based chemotherapy, such as cisplatin, by overcoming resistance mechanisms associated with low p27 expression. It is currently utilized in preclinical research to explore therapeutic strategies for enhancing tumor suppression and chemo-sensitivity.